Semaglutide Shows Remarkable Efficacy in Older Adults, Major Analysis Reveals
A major new analysis found that semaglutide (Ozempic, Wegovy) works exceptionally well in adults over 65, helping them lose substantial weight while improving heart and metabolic health. The findings suggest the drug may be particularly beneficial for older populations.
Major Clinical Findings
A major new analysis suggests semaglutide (Ozempic, Wegovy) works remarkably well in adults over 65, helping many lose substantial amounts of weight while improving heart and metabolic health. Participants taking the drug lost over 15% of their body weight, according to the analysis.
Clinical Implications
The results indicate that weight-loss medications traditionally studied in younger populations may offer significant therapeutic benefits for older adults, a demographic at high risk for cardiovascular disease and metabolic disorders.
Broader Context
This finding adds to the growing body of evidence supporting the use of GLP-1 receptor agonists for metabolic health beyond simple weight reduction.